Sparks commentary - Herantis Pharma

Healthcare

Sparks - Herantis Pharma

More on this equity
Herantis (HEL: HRTIS) presents positive Phase Ib update
Published by Arron Aatkar, PhD

Herantis Pharma has announced an encouraging update from its ongoing Phase Ib trial for lead asset HER-096, which is being developed as a potential disease-modifying treatment for Parkinson’s disease (PD). Analysis of the part 1 of the Phase 1b trial provided new pharmacokinetic data for HER-096, confirming the expected dosing interval of 2 or 3 subcutaneous doses per week. Further, part 2 of the study has commenced, including the first dosing of a participant diagnosed with PD. Top-line data are anticipated in Q325.

 

 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free